Terug
89
54
Dagbereik
€ 895,61
€ 908,67
52-Weeksbereik
€ 623,78
€ 1.133,95
Volume
1.728.145
50D / 200D Gem.
€ 1.024,73
/
€ 892,56
Vorige Slotkoers
€ 910,55
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 41,3 | 0,3 |
| P/B | 32,1 | 2,9 |
| ROE % | 101,4 | 3,7 |
| Net Margin % | 31,7 | 3,8 |
| Rev Growth 5Y % | 23,2 | 10,0 |
| D/E | 1,6 | 0,2 |
Koersdoel Analisten
Hold
€ 1.243,95
+37.8%
Low: € 985,00
High: € 1.350,00
Forward K/W
26,5
Forward WPA
€ 34,43
WPA Groei (sch.)
+0,0%
Omzet Sch.
82 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 60,97
€ 56,29 – € 66,45
|
130 B | 3 |
| FY2029 |
€ 55,40
€ 51,14 – € 60,38
|
120 B | 3 |
| FY2028 |
€ 49,21
€ 42,81 – € 55,86
|
110 B | 9 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 |
Fyrwald J Erik
Director
|
grant | 10 | € 989,12 | € 9.891 |
| Feb 17, 2026 |
Sulzberger Gabrielle
Director
|
grant | 5 | € 1.036,05 | € 5.180 |
| Feb 16, 2026 |
Brown Adrienne S
EVP, President LLY Imm
|
other | 952 | — | — |
| Feb 9, 2026 |
Yuffa Ilya
EVP&Pres, LLY USA&Global Capab
|
grant | 4.163 | € 1.044,67 | € 4.348.961 |
| Feb 9, 2026 |
Jonsson Patrik
EVP & President, LLY Int'l
|
grant | 4.818 | € 1.044,67 | € 5.033.220 |
| Feb 9, 2026 |
Brown Adrienne S
EVP, President LLY Imm
|
grant | 1.196 | € 1.044,67 | € 1.249.425 |
| Feb 9, 2026 |
Van Naarden Jacob
EVP,Pres LLY Oncology&HdCorpBD
|
grant | 4.866 | € 1.044,67 | € 5.083.364 |
| Feb 9, 2026 |
Montarce Lucas
EVP & CFO
|
grant | 1.365 | € 1.044,67 | € 1.425.975 |
| Feb 9, 2026 |
Ricks David A
President, Chair, and CEO
|
grant | 38.914 | € 1.044,67 | € 40.652.288 |
| Feb 1, 2026 |
Jonsson Patrik
EVP & President, LLY Int'l
|
other | 9.612 | — | — |
| Feb 1, 2026 |
Van Naarden Jacob
EVP,Pres LLY Oncology&HdCorpBD
|
other | 10.125 | — | — |
| Feb 1, 2026 |
Yuffa Ilya
EVP&Pres, LLY USA&Global Capab
|
other | 8.300 | — | — |
| Jan 20, 2026 |
Sulzberger Gabrielle
Director
|
grant | 5 | € 1.041,29 | € 5.206 |
| Dec 15, 2025 |
Fyrwald J Erik
Director
|
grant | 9 | € 1.062,19 | € 9.560 |
| Dec 15, 2025 |
LUCIANO JUAN R
Director
|
grant | 14 | € 1.062,19 | € 14.871 |
| Nov 17, 2025 |
Kaelin William G Jr
Director
|
grant | 215 | € 1.021,70 | € 219.666 |
| Oct 20, 2025 |
Fyrwald J Erik
Director
|
grant | 12 | € 808,96 | € 9.708 |
| Sep 15, 2025 |
LUCIANO JUAN R
Director
|
grant | 20 | € 748,19 | € 14.964 |
| Aug 12, 2025 |
Skovronsky Daniel
EVP, CSO & Pres. LRL & LLY Imm
|
buy | 1.000 | € 634,41 | € 634.405 |
| Aug 12, 2025 |
Sulzberger Gabrielle
Director
|
buy | 117 | € 641,18 | € 75.018 |
Belangrijkste Punten
Revenue grew 23,17% annually over 5 years — strong growth
Earnings grew 94,88% over the past year
ROE of 101,35% indicates high profitability
Net margin of 31,66% shows strong profitability
Generating 8,97B in free cash flow
P/E of 41,32 — premium valuation
Groei
Revenue Growth (5Y)
23,17%
Revenue (1Y)44,70%
Earnings (1Y)94,88%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
101,35%
ROIC32,26%
Net Margin31,66%
Op. Margin45,56%
Veiligheid
Debt / Equity
1,60
Current Ratio1,58
Interest Coverage37,34
Waardering
P/E Ratio
41,32
P/B Ratio32,14
EV/EBITDA29,91
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 44,70% | Revenue Growth (3Y) | 38,20% |
| Earnings Growth (1Y) | 94,88% | Earnings Growth (3Y) | 98,45% |
| Revenue Growth (5Y) | 23,17% | Earnings Growth (5Y) | 38,67% |
| Profitability | |||
| Revenue (TTM) | 65,18B | Net Income (TTM) | 20,64B |
| ROE | 101,35% | ROA | 18,35% |
| Gross Margin | 83,79% | Operating Margin | 45,56% |
| Net Margin | 31,66% | Free Cash Flow (TTM) | 8,97B |
| ROIC | 32,26% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 1,60 | Current Ratio | 1,58 |
| Interest Coverage | 37,34 | Dividend Yield | 0,01% |
| Valuation | |||
| P/E Ratio | 41,32 | P/B Ratio | 32,14 |
| P/S Ratio | 13,08 | PEG Ratio | 0,49 |
| EV/EBITDA | 29,91 | Dividend Yield | 0,01% |
| Market Cap | 852,73B | Enterprise Value | 888,07B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 65,18B | 45,04B | 34,12B | 28,54B | 28,32B |
| Net Income | 20,64B | 10,59B | 5,24B | 6,24B | 5,58B |
| EPS (Diluted) | 22,95 | 11,71 | 5,80 | 6,57 | 5,85 |
| Gross Profit | 54,62B | 36,62B | 27,04B | 21,91B | 21,01B |
| Operating Income | 29,70B | 17,50B | 10,79B | 8,65B | 7,93B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 112,48B | 78,71B | 64,01B | 49,49B | 48,81B |
| Total Liabilities | 85,94B | 64,44B | 53,14B | 38,71B | 39,65B |
| Shareholders' Equity | 26,54B | 14,19B | 10,77B | 10,65B | 8,98B |
| Total Debt | 42,50B | 33,64B | 25,23B | 16,24B | 16,88B |
| Cash & Equivalents | 7,16B | 3,27B | 2,82B | 2,07B | 3,82B |
| Current Assets | 55,63B | 32,74B | 25,73B | 18,03B | 18,45B |
| Current Liabilities | 35,23B | 28,38B | 27,29B | 17,14B | 15,05B |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#13 of 157
Custom
Full Throttle
#44 of 146
Recente Activiteit
Ingestapt
Growth Investing (Philip Fisher)
Mar 24, 2026
Ingestapt
Full Throttle
Mar 24, 2026